Aminoglycosides for Peritonitis

Role in Different Types of Peritonitis

The American College of Physicians recommends third-generation cephalosporins, such as cefotaxime, as the established first-line treatment for Spontaneous Bacterial Peritonitis (SBP), rather than aminoglycosides, due to their effectiveness and safety profile in patients with SBP 1
The World Society of Emergency Surgery guidelines state that aminoglycosides are not recommended for routine empiric treatment of community-acquired intra-abdominal infections in adults, and should be reserved for specific scenarios, such as patients with documented beta-lactam allergies or suspected multidrug-resistant gram-negative bacteria 2
Aminoglycosides lack anaerobic coverage and must be combined with metronidazole if used for peritonitis treatment, as recommended by the World Society of Emergency Surgery guidelines 2
The Infectious Diseases Society of America recommends that aminoglycoside-containing regimens, such as gentamicin + ampicillin + clindamycin, can be used successfully for decades in children with complicated intra-abdominal infections, including peritonitis, although broader-spectrum single agents are now preferred for perforated appendicitis with peritonitis 3, 4
Aminoglycosides fail to achieve adequate tissue penetration into pancreatic tissue at standard IV doses, making them unsuitable for pancreatic infections, as stated in the World Journal of Emergency Surgery 5

The American College of Clinical Pharmacy recommends therapeutic drug monitoring to minimize toxicity, primarily ensuring trough concentrations are sufficiently low to prevent renal toxicity, with target peak concentrations of approximately 3 μg/mL and trough concentrations <1 μg/mL when using divided dosing 6, 7

The World Society of Emergency Surgery guidelines recommend determining peritonitis type and assessing for specific indications in adults, such as beta-lactam allergy or suspected multidrug-resistant gram-negative bacteria, before considering aminoglycoside use 1, 2
The Infectious Diseases Society of America recommends considering gentamicin-based regimens as an alternative to carbapenems for pediatric peritonitis 3, 4

The World Society of Emergency Surgery guidelines warn against using aminoglycosides as monotherapy due to their lack of anaerobic coverage, and against using them for routine community-acquired peritonitis in adults due to toxicity risks 2
The Infectious Diseases Society of America advises against assuming pediatric and adult dosing strategies are interchangeable, as aminoglycosides remain more acceptable in pediatric practice 3, 4
The World Journal of Emergency Surgery warns against using aminoglycosides for pancreatic infections due to inadequate tissue penetration at standard doses 5

The European Association for the Study of the Liver recommends third-generation cephalosporins, such as cefotaxime 2g IV every 6-12 hours, as first-line treatment for Spontaneous Bacterial Peritonitis (SBP) in cirrhosis, rather than gentamicin, due to high nephrotoxicity risk in patients with already compromised renal function 8, 9
The World Journal of Emergency Surgery suggests that aminoglycosides, such as gentamicin, are not recommended for routine empiric treatment of community-acquired intra-abdominal infections, but may be reserved for specific scenarios like documented beta-lactam allergies or suspected multidrug-resistant gram-negative bacteria 10

The American Heart Association recommends standard IV dosing of gentamicin at 3-6 mg/kg/day divided every 8 hours (adults: 3-5 mg/kg/day) for serious infections, with adjustments for renal function 11, 12
The Clinical Microbiology and Infection journal emphasizes the importance of mandatory monitoring of both peak and trough serum concentrations to balance efficacy against nephrotoxicity and ototoxicity, with target peak concentration of 4-6 mcg/mL and target trough concentration of <2 mcg/mL 13

The Hepatology journal suggests that the standard duration of treatment for peritonitis is 7-10 days, but for PD peritonitis specifically, 5-7 days is typical, with de-escalation based on culture results and clinical improvement 9
The World Journal of Emergency Surgery recommends de-escalating gentamicin once gram-negative coverage is no longer needed, and avoiding its use beyond 48-96 hours without culture confirmation of gram-negative infection requiring aminoglycoside coverage 10, 9

The presence of anaerobes in the peritoneal cavity is assumed based on the pathophysiology of intra-abdominal infections, making monotherapy with any single agent inadequate unless it covers both spectrums 14
A systematic review demonstrated poorer clinical success with aminoglycosides compared to all other comparators (OR 0.65; 95% CI 0.46-0.92) 15

Peritonitis patients treated with aminoglycosides experienced greater decreases in residual kidney function compared to those treated with less nephrotoxic antibiotics 16
This is particularly critical in peritoneal dialysis patients, where preservation of residual kidney function directly impacts mortality and quality of life 16

First-line options, such as Cefotaxime, ceftriaxone, or ciprofloxacin plus metronidazole, provide superior clinical outcomes with better safety profiles 15
These regimens achieved better clinical cure rates (OR 3.21; 95% CI 1.49-6.92 for cephalosporins; OR 1.74; 95% CI 1.11-2.73 for fluoroquinolones with anti-anaerobic agents) 15
Piperacillin-tazobactam or carbapenems (meropenem, imipenem) are preferred for critically ill patients or those with risk factors for multidrug-resistant organisms 15
If ESBL-producing organisms are confirmed on culture, ertapenem or newer agents like ceftolozane-tazobactam (with metronidazole) are appropriate 17

Do not assume culture-negative peritonitis excludes anaerobes—they are notoriously difficult to culture and are presumed present based on the source of infection 14